Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DSM-IV Schizophrenia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44400   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    205 result(s) found for: DSM-IV Schizophrenia. Displaying page 2 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-003529-41 Sponsor Protocol Number: ABR58805 Start Date*: 2017-02-22
    Sponsor Name:University Medical Center Utrecht
    Full Title: CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia
    Medical condition: Schizophrenia patients
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000479-11 Sponsor Protocol Number: 12396A Start Date*: 2008-07-21
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia
    Medical condition: Lu 31-130 is under development by H. Lundbeck A/S as an antipsychotic in the treatment of schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039639 Schizophrenia, paranoid type PT
    9.1 10039637 Schizophrenia, catatonic type PT
    9.1 10039638 Schizophrenia, disorganised type PT
    9.1 10052792 Schizophrenia, undifferentiated type PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006967-22 Sponsor Protocol Number: R076477-SCH-3020 Start Date*: 2007-10-08
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects with Schizophrenia
    Medical condition: Subjects 18 – 65 years of age, who meets the DSM-IV criteria for schizophrenia with a PANSS total score at screening of 60-100 inclusive.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) SE (Prematurely Ended) GR (Completed) EE (Completed) FR (Completed) GB (Prematurely Ended) IT (Completed) SK (Completed) LV (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005451-32 Sponsor Protocol Number: F17464GE201 Start Date*: 2014-07-09
    Sponsor Name:Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)
    Full Title: Effects of F17464 in acute exacerbation of schizophrenia.
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-002538-38 Sponsor Protocol Number: 331-10-231 Start Date*: 2011-10-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
    Medical condition: Acute Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10001064 Acute schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002513-11 Sponsor Protocol Number: 331-10-230 Start Date*: 2012-01-09
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed dose OPC-34712 (4, 2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia
    Medical condition: Acute Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10001064 Acute schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002713-35 Sponsor Protocol Number: AXCT01-01-03-2013 Start Date*: 2014-07-29
    Sponsor Name:MediPsych SA
    Full Title: Randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003156-35 Sponsor Protocol Number: EXPSY 0105 Start Date*: 2005-12-01
    Sponsor Name:Department of Psychiatry and Psychotherapy (Cologne)
    Full Title: Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study
    Medical condition: Patients with schizophrenia and cannabis abuse/dependency will be randomized to ziprasidone or clozapine treatment. Dose of medication and frequency of administration will be flexible and adjustab...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014469-19 Sponsor Protocol Number: RECOVERY[OCTUMI-4] Start Date*: 2010-08-17
    Sponsor Name:University of Oxford [...]
    1. University of Oxford
    2.
    Full Title: OCTUMI-4: Evaluation of Mirtazapine and Folic Acid for Schizophrenia: A randomised, double-blind, 2x2 factorial trial
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018416-33 Sponsor Protocol Number: 2009_37/1001 Start Date*: 2010-07-13
    Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
    Full Title: Effets du Fénofibrate durant la première année de schizophrénie (effects of Fenofibrate® in first year of schizophrenia)
    Medical condition: schizophrénia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039626 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000520-14 Sponsor Protocol Number: NL46653 Start Date*: 2014-07-31
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prednisolone addition for atients with recent onset psychotic disorder: the role of immune-modulating strategies in the treatment of psychosis.
    Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022181-28 Sponsor Protocol Number: 13639A Start Date*: 2011-02-07
    Sponsor Name:H. Lundbeck A/S
    Full Title: A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039638 Schizophrenia, disorganised type PT
    14.0 10037175 - Psychiatric disorders 10039639 Schizophrenia, paranoid type PT
    14.0 10037175 - Psychiatric disorders 10052792 Schizophrenia, undifferentiated type PT
    14.0 10037175 - Psychiatric disorders 10039637 Schizophrenia, catatonic type PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001845-40 Sponsor Protocol Number: R092670-PSY-3005 Start Date*: 2005-08-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia
    Medical condition: Schizophrenia according to DSM-IV-TM [disorganized type (295.10), catatonic type (295.20), paranoid type (295.30), residual type (295.60) or undifferentiated type (295.90)]
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-001711-31 Sponsor Protocol Number: D1050238 Start Date*: 2012-02-29
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003519-33 Sponsor Protocol Number: D1443L00003 Start Date*: 2007-01-25
    Sponsor Name:AstraZeneca UK Limited
    Full Title: RAPID - An Open-Label, Randomised, Multicentre Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immedicate Release), over 14 days, in Acute Schizophrenia / Schizoaffecti...
    Medical condition: Acute Schizophrenia and Schizoaffective Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001523-39 Sponsor Protocol Number: D1050300 Start Date*: 2013-11-08
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000060-42 Sponsor Protocol Number: D1001066 Start Date*: 2017-03-15
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002048-29 Sponsor Protocol Number: RGH-MD-06 Start Date*: 2012-03-29
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-019897-33 Sponsor Protocol Number: 2522518514 Start Date*: 2011-04-14
    Sponsor Name:erasmus mc
    Full Title: Selective D1 activation by addition of L-Dopa to antipsychotic treatment in patients with schizophrenia
    Medical condition: patients with psychotic symptoms, diagnosed with schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017852-28 Sponsor Protocol Number: H8Y-MC-HBBM(a) Start Date*: 2010-05-04
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 versus Placebo in Patients with DSM-IVTR Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 21 03:22:20 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA